Medicinal – Page 39

Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program

mycolabadmin

Switzerland operates a unique program allowing controlled use of psychedelics (LSD, psilocybin) and MDMA to help patients with serious mental health conditions that haven’t responded to standard treatments. Since 2014, about 100 doctors have treated 700+ patients with these substances as part of therapy sessions. The program requires careful patient screening, informed consent, and outcome reporting, with patients typically receiving 2-4 treatments over 12 months. Most patients showed significant improvement in their conditions, though some experienced side effects like nausea or headaches.

Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study

mycolabadmin

This study examines how antidepressant medications (like SSRIs) affect the experience of classic psychedelics such as psilocybin and LSD. Researchers found that people taking these antidepressants experienced less intense emotional and mystical effects from psychedelics, but surprisingly, both groups showed similar improvements in mood and well-being several weeks later. This raises important questions about whether patients need to stop their antidepressants before using psychedelics therapeutically.

Comparative Mitogenomics Provides Valuable Insights for the Phylogeny and New DNA Barcodes of Ganoderma

mycolabadmin

Researchers successfully sequenced the mitochondrial genomes of four commonly cultivated medicinal mushroom species in the Ganoderma genus. They identified two specific genes, atp9 and nad4L, as reliable molecular barcodes that can accurately distinguish between different Ganoderma species. These DNA barcodes serve as a universal identification tool, similar to product barcodes in supermarkets, helping to identify and classify Ganoderma species for medicinal and commercial purposes.

Psilocybin During the Postpartum Period Induces Long-Lasting Adverse Effects in Both Mothers and Offspring

mycolabadmin

A new study shows that psilocybin, a psychedelic compound being tested for postpartum depression, may actually cause harm during the breastfeeding period. While the drug helped non-pregnant mice feel less anxious, it made postpartum mothers more anxious and worsened their caregiving behaviors. Even more concerning, baby mice exposed to psilocybin through breast milk developed mood and social problems as adults, suggesting potential lasting risks for human infants.

The effect of psilocybin on empathy and prosocial behavior: a proposed mechanism for enduring antidepressant effects

mycolabadmin

This review examines how psilocybin may help treat depression by increasing empathy and prosocial behavior. While psilocybin leaves the body within hours, its antidepressant effects can last months, and researchers believe empathy and helping others may explain this lasting benefit. The authors suggest psilocybin starts a positive cycle where increased empathy leads to helping others, which boosts mood and well-being, which further reinforces empathetic behavior.

Bioactive Potential of Balkan Fomes fomentarius Strains: Novel Insights into Comparative Mycochemical Composition and Antioxidant, Anti-Acetylcholinesterase, and Antiproliferative Activities

mycolabadmin

This study examines three strains of Fomes fomentarius mushroom from the Balkan region, revealing they are rich sources of beneficial compounds including polyamines and phenolic compounds. These extracts demonstrated strong antioxidant properties and potential neuroprotective effects, suggesting they could help prevent diseases related to oxidative stress and aging. The research supports the traditional use of this mushroom in folk medicine and highlights its potential as a natural supplement for health promotion.

The Effect of Fungal Nutraceutical Supplementation on Postoperative Complications, Inflammatory Factors and Fecal Microbiota in Patients Undergoing Colorectal Cancer Surgery with Curative Intent: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial

mycolabadmin

Researchers tested whether a supplement made from nine different medicinal mushroom types could reduce complications after colorectal cancer surgery. While the supplement didn’t significantly reduce overall complications, it did appear to boost immune function in patients undergoing traditional surgery and favorably changed the composition of gut bacteria. The supplement was well-tolerated with no serious side effects.

Modulating the gut microbiota is involved in the effect of low-molecular-weight Glycyrrhiza polysaccharide on immune function

mycolabadmin

Researchers studied a natural compound from licorice called Glycyrrhiza polysaccharide (GP) to see if it could help restore immune function in mice weakened by chemotherapy. GP treatment improved intestinal health, boosted immune cells, and changed the gut bacteria composition to favor beneficial strains. The study shows that GP works partly by modifying which bacteria live in the gut, which then support the immune system. This research suggests GP could be useful as a natural supplement for strengthening immunity and treating intestinal inflammation.

Body mass index (BMI) does not predict responses to psilocybin

mycolabadmin

Researchers investigated whether a person’s body weight affects how they respond to psilocybin-assisted therapy. Analyzing 77 participants across three studies, they found that BMI did not predict how intensely people experienced the drug or how much their mental health improved afterward. This surprising finding suggests that everyone might benefit from the same fixed dose of psilocybin rather than doses adjusted to body weight, making therapy simpler and more cost-effective to deliver at scale.

Fungal Drug Discovery for Chronic Disease: History, New Discoveries and New Approaches

mycolabadmin

This article examines how fungi have provided humanity with some of the most important medicines ever created, including penicillin, drugs that prevent organ rejection, and cholesterol-lowering statins. Many of these fungal compounds work as medicines because they target processes that are similar in both fungi and humans, helping them survive competition with other fungi while coincidentally treating human diseases. New researchers are now using modern genetic tools to discover additional fungal medicines, with several promising candidates currently being tested in clinical trials for cancer, depression, and other chronic diseases.

Research Topic: Medicinal